Target intelligence / Profile preview

Beta-transducin repeat-containing protein (BTRC)

Target
BTRC
Molecular classification
E3 ubiquitin ligase, F-box protein, SCF complex component, Enzyme
01

Overview

Beta-transducin repeat-containing protein (BTRC), also known as beta-TrCP1, is a critical F-box protein that serves as the substrate recognition subunit of the SCF (Skp1-Cullin1-F-box) E3 ubiquitin ligase complex [UniProt: P63151]. It plays a pivotal role in cellular homeostasis by mediating the phosphorylation-dependent ubiquitination and subsequent proteasomal degradation of key regulatory proteins, including beta-catenin, IkappaB, and CDC25A [PubMed: 15181464]. Through these interactions, BTRC modulates essential signaling pathways such as Wnt/beta-catenin and NF-kappaB, which govern cell proliferation, survival, and the immune response [NCBI Gene: 8945]. In the context of disease, BTRC is often dysregulated in various malignancies, including colorectal and pancreatic cancers, where it can function as either an oncogene or a tumor suppressor depending on the specific cellular context and the stability of its substrates [PubMed: 24513166]. Furthermore, BTRC is exploited by viruses like HIV-1, which uses its Vpu protein to hijack the ligase and degrade CD4, facilitating viral release [PubMed: 9843217]. Therapeutically, BTRC is being explored as a recruitment module for Proteolysis Targeting Chimeras (PROTACs) to induce the degradation of neo-substrates, although its broad range of natural targets poses challenges for achieving high specificity and minimizing systemic toxicity [PubMed: 32111836].

Other names
F-box/WD repeat-containing protein 1AFBXW1Abeta-TrCP1BTRCPFBXW1F-box and WD repeats protein beta-TrCP
02

Mechanism of action

Substrate recognition and recruitment for SCF-type E3 ubiquitin ligase-mediated polyubiquitination and subsequent 26S proteasomal degradation.

03

Biological functions

Protein ubiquitinationProteasomal degradationWnt signaling pathwayNF-kappaB signaling pathwayCell cycle regulationSignal transductionApoptosis regulation
04

Disease associations

CancerInflammationInfectionHIV-1 infectionAutoimmune disease
05

Safety considerations

Systemic toxicity due to pleiotropic effects on essential signaling pathwaysPotential for off-target protein degradation when used in PROTACsDisruption of homeostatic Wnt and NF-kappaB signalingRisk of promoting oncogenesis by stabilizing or degrading context-dependent substrates
06

Interacting drugs

PROTACs (as E3 ligase recruiter)

3 more in the full profile.

07

Biomarkers

beta-catenin protein levelsIkappaBalpha phosphorylation/degradation statusBTRC mRNA expressionCDC25A protein stability

Beyond the preview

Go deeper on Beta-transducin repeat-containing protein (BTRC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta-transducin repeat-containing protein (BTRC).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call